3rd Quarter - Report

NOVARTIS for NOVARTIS

Firm
Client
Income
—
Expenses
$1,140,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Free Trade Agreements - Intellectual Property and Transparency Provisions - Free Trade Agreements Access to Medicines Issues Global Health Issues India, China and Canada IP and Market Access Issues Sub-standards Medicines Quality of Medicines International Market Access and Intellectual Property Issues Biopharmaceutical Innovation Policies Colombia Intellectual Property Regulatory Cooperation USTR Special 301 Report/National Trade Estimate Trade Policy KORUS Tariffs CFIUS USMCA US Swiss Trade Agreement

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); U.S. Agency for International Development (USAID); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); State, Dept of (DOS); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); White House Office; SENATE; U.S. Trade Representative (USTR)

Taxation/Internal Revenue Code TAX

OECD Digital Tax ACA Pharmaceutical Industry Fee Exclusions Orphan Drug Tax Mobile Workforce Thin Capitalization Rules 163(j) Base Erosion Surtax Tax Cuts & Jobs Act Implementation Innovation Box Expended FDII Treasury Proposed BEAT Regulations Tax Treaties

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); White House Office; State, Dept of (DOS); U.S. Agency for International Development (USAID); SENATE; Office of Management & Budget (OMB)

Copyright/Patent/Trademark CPT

S.659 - Biologic Patent Transparency Act Data Exclusivity Intellectual Property Biopharmaceutical Innovation Policy Issues Biologics Data Protection issues Patent Litigation Reform and Issues Related to Post Grant Proceedings at PTO BPCIA Hatch-Waxman Patents Inter Partes Review at PTO Biosimilars S 1416 - Affordable Prescriptions for Patients Act of 2019 H.R.465 - Prescription Drug Price Relief Act of 2019 H.R.938 - BLOCKING Act of 2019 H.R.987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R.990 - Hatch-Waxman Integrity Act of 2019 H.R.1046 - Medicare Negotiation and Competitive Licensing Act of 2019 H.R.2375 - Preserve Access to Affordable Generics and Biosimilars Act H.R.2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act S.64 - Preserve Access to Affordable Generics and Biosimilars Act S.102 - Prescription Drug Price Relief Act of 2019 Bayh-Dole march-in rights policy issues S.440 - Preserving Access to Cost Effective Drugs Act (PACED Act)(Sovereign immunity issues before the PTAB) Section 101

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH New —
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —

Contacted: U.S. Agency for International Development (USAID); White House Office; Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); State, Dept of (DOS); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 659 (116th), H.R. 465 (116th), H.R. 938 (116th), H.R. 987 (116th), S. 440 (116th), H.R. 2375 (116th), H.R. 2700 (116th), H.R. 990 (116th), H.R. 1046 (116th), S. 64 (116th), S. 102 (116th)

Health Issues HCR

S.2543 - Prescription Drug Pricing Reduction Act of 2019 HR 3 H.R.5997 - Ensuring Patient Access to Critical Breakthrough Products Act of 2018 HR 938: Bringing Low-Cost Options and Competition while Keeping Incentives for New Generics Act HR 1520: Purple Book Continuity Act HR 1503: Orange Book Transparency Act HR 1499: Protecting Consumer Access to Generic Drugs Act HR 2113:Speeding Access to Already Approved Pharmaceuticals Act of 2017 HR 5997:Ensuring Patient Access to Critical Breakthrough Products Act of 2018 Senate SPIKE Act Fast Generics Cell & Gene Therapy, including reimbursement 340B Drug Discount Program Drug Importation REMS Creates Act Drug Cost/Pricing Biosimilars Reimbursement Outcomes based Contracting Part D Non-interference Orphan Drugs Drug Pricing Transparency Virtual Clinical Trials Part D Benefit Redesign Biosimilar Pass Through Payments Value Based Pricing USMCA Medicaid Payment Reform AMP Cap Labor HHS Appropriations S 1895 - Lower Health Care Costs Act HR 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R.478 - Safe and Affordable Drugs from Canada Act of 2019 H.R.965 - CREATES Act of 2019 H.R.985 - FAST Generics Act of 2019 H.R.1093 - Stop Price Gouging Act H.R.1332 - Fair Care Act of 2019 H.R.1506 - FAIR Generics Act H.R.2011 - Protecting Access to Biosimilars Act of 2019 H.R.2069 - SPIKE Act H.R.2087 - Drug Price Transparency Act H.R.2113 - Prescription Drug STAR Act H.R.2296 - FAIR Drug Pricing Act of 2019 H.R.3327 - Drug Price Transparency for Medicare Patients Act of 2019 H.R.3408 - EXEMPT Act S.61 - Safe and Affordable Drugs from Canada Act of 2019 S.340 - CREATES Act of 2019 S.474 - Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.1140 - Protecting Access to Biosimilars Act of 2019 S.1384 - Prescription Drug Rebate Reform Act of 2019 S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019 S.1437 - Drug-price Transparency in Communications (DTC) Act S.1224 - Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (Stop STALLING Act) S.1227 - Prescription Pricing for the People Act of 2019

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —

Contacted: Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); U.S. Agency for International Development (USAID); SENATE; U.S. Trade Representative (USTR); White House Office; Health & Human Services, Dept of (HHS); State, Dept of (DOS)

Bills named: H.R. 2113 (116th), S. 1140 (116th), H.R. 1520 (116th), H.R. 1093 (116th), H.R. 987 (116th), H.R. 938 (116th), H.R. 1506 (116th), S. 1227 (116th), H.R. 1499 (116th), S. 1437 (116th), S. 2543 (116th), H.R. 985 (116th), S. 1391 (116th), S. 61 (116th), S. 340 (116th), H.R. 1503 (116th), H.R. 3408 (116th), H.R. 2296 (116th), H.R. 1332 (116th), S. 1224 (116th), H.R. 478 (116th), H.R. 5997 (116th), H.R. 3327 (116th), H.R. 2011 (116th), S. 1384 (116th), H.R. 2087 (116th), H.R. 2069 (116th), H.R. 3 (116th), S. 474 (116th), H.R. 965 (116th)

Foreign Relations FOR

Foreign Investment Risk Review Modernization Act of 2017 (FIRMMA) CFIUS Reform Foreign Agents Registration Act (FARA) Reform S.1762 - Foreign Agents Disclosure and Registration Enhancement Act of 2019

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —

Contacted: SENATE; Commerce, Dept of (DOC); Office of Management & Budget (OMB); State, Dept of (DOS); U.S. Agency for International Development (USAID); HOUSE OF REPRESENTATIVES; White House Office; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); U.S. Trade Representative (USTR)

Bills named: S. 1762 (116th)

Medicare/Medicaid MMM

AMP Cap H.R 3 S.2543 - Prescription Drug Pricing Reduction Act of 2019 H.R. 1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019 Biosimilars Medicare Part D Drug Pricing Part B Outcomes Based Contracts Generics Innovative Pharmaceuticals Cell and Gene Therapy Medicaid Alternative Payment Models H.R.275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R.448 - Medicare Drug Price Negotiation Act H.R.937 - Right Rebate Act of 2019 Medicare Part A

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —

Contacted: U.S. Agency for International Development (USAID); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); White House Office; Commerce, Dept of (DOC); State, Dept of (DOS); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 448 (116th), H.R. 1046 (116th), H.R. 275 (116th), H.R. 937 (116th), S. 377 (116th), H.R. 3 (116th), S. 2543 (116th)

Budget/Appropriations BUD

FDA Appropriations funding for Generic Drugs Certified Importer Program (CIP) Reconciliation Gx Drug Labeling Biosimilars Importation Drug Pricing Value of Medicine Blocking Act H.R.21 - Consolidated Appropriations Act, 2019 H.R.265 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019 H.R.648 - Consolidated Appropriations Act, 2019 H.R.2500 - National Defense Authorization Act for Fiscal Year 2020 H.R.2740 - Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —

Contacted: Commerce, Dept of (DOC); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); SENATE; Centers For Medicare and Medicaid Services (CMS); U.S. Agency for International Development (USAID); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); White House Office; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS)

Bills named: H.R. 648 (116th), H.R. 21 (116th), H.R. 2740 (116th), H.R. 265 (116th), H.R. 2500 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.